Abstract
The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specificGPCRsto either stimulate cyclicAMPformation, as exemplified byGs‐protein‐coupled adenosine receptors (A2AandA2B), or inhibit AC activity, in the case ofGi/o‐coupled adenosine receptors (A1andA3). Recent advances in our understanding ofGPCRstructure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosineA1andA3receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single‐cell ligand‐binding kinetics and the effects ofA1‐ andA3‐receptor allosteric modulators onin vivopharmacology.Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visithttp://dx.doi.org/10.1111/bph.2014.171.issue‐5

This publication has 115 references indexed in Scilit: